The CDR3 loops of both antibodies and TCRs are a site of extensive diversity, due to their formation from the Division of Biology Howard Hughes Medical Institute assembly of two or more gene segments during lymphocyte development. In antibodies, the overall mode of California Institute of Technology Pasadena, California 91125 pairing of variable heavy (V H ) with variable light (V L ) domains is conserved for all V H -V L combinations, such that the CDR3Јs from each domain are at the center of the site, flanked by the CDR1 and CDR2 regions from each B and T lymphocytes of the immune system employ a domain. The same arrangement of CDRs is found in the highly effective diversity-generating machinery to en-2C TCR heterodimer structure (Figure 1) . Three of the sure that their receptors, antibodies and T cell receptors TCR heterodimer domains (V␣, V␤, and C␤) are structur-(TCRs), respectively, have the capacity to recognize an ally homologous to their antibody counterparts, but the enormous array of antigens. Indeed, antibodies can be constant region of the ␣ chain (C␣) shows an unusual raised against many kinds of molecules that are perfolding topology: instead of the well-characterized ␤ ceived as foreign to the host, including proteins, carbosandwich fold of an antibody constant domain or of TCR hydrates, small organic compounds, and nucleic acids.
placement, they determined the positions of both proIn the intervening 20 plus years, many pivotal discovteins in the cocrystal. For the noncrystallographer, this eries have facilitated a molecular description of MHCmeans that they used the coordinates of the high resolurestricted T cell recognition (reviewed in Janeway and tion structures of each protein in a search of the cocrysTravers, 1996): TCRs were found to resemble the antigen tal diffraction data and found rotation and translation binding, or F ab , portions of antibodies in sequence and domain organization; the form of antigen recognized by a TCR was discovered to be a peptide fragment bound to an MHC molecule; and crystal structures of MHC/ peptide complexes revealed a surface composed of atoms derived from both the peptide and the MHC molecule. Taken together, these discoveries made the dual recognition requirements of TCRs (for the right antigen as well as the right MHC molecule) easier to understand, but direct visualization of a TCR binding its MHC/peptide ligand or even of a TCR alone eluded the efforts of many laboratories for years. This gap in our knowledge of TCR recognition has been filled by recent publications of crystallographic analyses of a TCR heterodimer and of TCRs binding to their MHC/peptide ligands (Garboczi et al., 1996; Garcia et al., 1996) . Structure of the 2C TCR The 2.5 Å crystal structure of a mouse TCR ␣␤ heterodimer (designated 2C), reported by K. Christopher Garcia, Ian Wilson, and colleagues (Garcia et al., 1996) , confirms what was suspected from the information provided by TCR sequences and crystal structures of TCR pieces (Bentley et al., 1995; Fields et al., 1995) : the pairing of TCR variable (V) domains is similar to the pairing of antibody V domains, so that the TCR combining site for antigen resembles an antibody combining site. In the combining sites of antibodies, regions of hypervariable amino acid sequence are located in loops that connect ␤ strands. The region of contact with antigens primarily contain six CDRs, three contributed from each V domain.
parameters that describe the location of each molecule Class I and class II MHC molecules have similar three dimensional structures, both containing a membranewithin the cocrystal unit cell. Having found these parameters, they could position the 2C TCR on top of the distal portion consisting of an 8-stranded ␤-pleated sheet topped by two ␣ helices (Figure 2 ; reviewed in H-2K b /peptide complex. The final structure solution will include building a model into the electron density maps Stern and Wiley, 1994) . In each case, this region is formed from two subdomains (␣1 and ␣2, class I; ␣1 obtained using the molecular replacement phases, and refinement of the model. At the reported stage of the and ␤1, class II), each composed of a 4-stranded ␤ sheet and a single helix. Short (8-9 residues for class I; 14-20 structure determination, a detailed analysis of the molecular interactions between the TCR and MHC molecule residues for class II) peptides are accommodated within the groove between the helices. What often comes as a surprise for immunology studoes a TCR contact the MHC/peptide surface, and do all TCRs contact MHC/peptide complexes in a similar dents and even seasoned immunologists is that most of the available surface area of a bound peptide is inacorientation?) is addressed in this analysis, and the results can be compared to the 2.6 Å refined structure of cessible to a TCR. Thus TCR recognition of a peptide antigen is accomplished directly by relatively few cona human TCR/MHC/peptide complex recently reported by David Garboczi, Partho Ghosh, Don Wiley and coltacts with peptide side chains that point "up" (toward the TCR). Other peptide side chains could be recognized leagues (Garboczi et al., 1996) . The MHC/Peptide Ligands of TCRs indirectly by subtle conformational changes of MHC residues when different peptides are bound, but for the Before describing the TCR/MHC/peptide structures, it is worthwhile to discuss the MHC/peptide ligands that most part, the carbon-␣ backbones of class I or class II MHC molecules are remarkably similar regardless of TCRs recognize. MHC molecules come in two varieties: class I and class II, which have different cellular distribuwhat peptide is bound. During T cell maturation in the thymus, TCRs are subtions and bind different kinds of peptides. Class I MHC molecules are found on nearly all cells in the body. They jected to two forms of quality control: they must have some propensity for binding self MHC molecules (posipresent peptides derived from proteins degraded in the cytosol, alerting the immune system to the presence of tive selection) because they will be required to respond to foreign peptides complexed with self MHC molecules intracellular pathogens such as viruses. In general, class I MHC/peptide complexes are recognized by cytotoxic in the periphery, but they must not bind them too tightly (negative selection) because of the potential for autoim-T cells that carry the T cell coreceptor CD8, resulting in killing of the target cell. Class II MHC molecules are mune reactions. Less than 5% of T cells bear receptors that pass these tests; the rest die in the thymus and expressed on a more limited subset of cells, mainly antigen presenting cells involved in interactions with their receptors are not used. TCRs have an intrinsic affinity for MHC molecules (apparently germ-line en-T cells expressing the coreceptor CD4. Class II MHC molecules bind peptides derived from exogenous anticoded according to recent results; Zerrahn et al., 1997), which might therefore show up as a common mode of gens, such as proteins engulfed by a macrophage. Recognition of a class II MHC/peptide complex by a CD4-binding for all TCR/MHC/peptide complexes. The inherent bias of TCRs for MHC recognition could also explain positive T cell can result in activation of a B cell to produce antibody, or activation of an infected macrothe large numbers of T cells that react to foreign MHC molecules (alloreactivity), leading to host rejection of phage to destroy intracellular bacteria. transplanted skin or organs from non-MHC-matched responds. By sequencing TCR genes from T cell hybridomas generated after immunization, the TCR contact donors.
Mapping TCR Footprints on Their Ligands
points for the peptide residues that were changed were mapped. Results from three peptide variants suggested These ideas have prompted a number of studies to map the orientations of TCRs onto their MHC/peptide lithat CDRs 1 and 2 of TCR ␣ lie over the N-terminal region of the peptide (left in Figure 2E ), CDR3 of the ␣ gands. Because the potential for TCR diversity is heavily concentrated in the CDR3 regions, these loops were chain interacts with a central position of the peptide, and CDR3 of the ␤ chain lies over the C-terminal region suggested to contact the most variable part of the TCR's MHC/peptide ligand (i.e., the peptide), with the less poof the peptide (right in Figure 2E ), results consistent with the idea that the TCR is aligned diagonally across the tentially diverse CDR1 and CDR2 loops aligned over the portion of the TCR ligand that remains more constant MHC/peptide surface, although a detailed comparison suggests some differences between recognition of class (i.e., the MHC helices; reviewed in Jorgensen et al., 1992, and references therein). Two recent studies modify the II and class I molecules by TCRs (Sant'Angelo et al., 1996) . predictions of the earlier models that emphasized the importance of CDR3 regions in peptide contacts. Figure 3A) , the direction of the line that joins the two centrally located CDR3 loops of the partial T cell responses, and are called partial agonists. Garboczi et al. announce that they have also crystallized TCR is ‫03ف‬Њ from perpendicular to the viewer. When the MHC molecule is rotated about its long axis (vertical in the A6 TCR as a complex with HLA-A2 and a peptide that behaves as a partial agonist. The eventual compari- Figure 3 ) so that the two highest points line up, the TCR is now aligned with the direction between its CDR3 son of the same TCR interacting with an agonist versus a partial agonist peptide may shed light on how recogniregions almost exactly perpendicular to the page. In this orientation, the MHC ␣1 and ␣2 domains resemble a tion of two very similar ligands sends different signals to the cytoplasm of the T cell. If the A6 TCR shows the saddle (in both its equine-related and mathematical definitions), with the A6 TCR appearing as a slightly tilted same conformation when it recognizes both peptides (as this author suspects it will), mechanisms involving (legless) rider and the 2C TCR seemingly more firmly seated ( Figures 3B and 3C) . The tilted orientation of the differences in affinities and/or off-rates that affect the duration of the binding event (e.g., Matsui et al., 1994) , A6 TCR compared to the 2C TCR (which might be related to the greater length of its V␤ CDR3 region) results in rather than induced conformational changes, will have to be invoked to explain the triggering of different cytothe absence of contacts between CDR2 of the A6 ␤ chain and MHC or peptide residues on the right side of plasmic signaling pathways following TCR engagement of the same MHC molecule bearing slightly different the groove (as defined in Figure 2B ). Judging from the differences between the A6 and 2C complexes, it seems peptides. Indeed, the issue of how TCR recognition of any MHC/peptide complex results in cytoplasmic signallikely that minor rearrangements of the V␣-V␤ interface in other TCRs (as has been observed in comparisons ing remains to be resolved. One next step will be the comparison of the structure of a TCR in its liganded of V H -V L domain pairing in antibodies) would place the CDR2 region of other TCR ␤ chains in position to contact versus unliganded state, undoubtedly a possibility in the near future. Now that TCRs have been shown to the C-terminal region of the MHC ␣1 domain helix, as appears to be occurring in the interaction between the crystallize, whether produced in eukaryotic (Garcia et al., 1996) or prokaryotic (Bentley et al., 1995; Fields et 2C TCR and its ligand. Speculations regarding a dimeric TCR/MHC signaling al. , 1995; Garboczi et al., 1996) cells, we can look forward to a multitude of other exciting new structures. assembly (reviewed in Fields and Mariuzza, 1996) are called into question by both recent TCR structural stud-
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